Overview of clinical trials evaluating the PI3K/AKT/mTOR pathway in hepatocellular carcinoma, highlighting therapeutic prospects.
Hepatocellular carcinoma (HCC) is the most common primary liver tumor and the third leading cause of cancer-related mortality globally. The phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapam... | Find, read and cite all the research you need on Tech Science Press
No takes yet. Share an insight, caveat, or question.
Khorasani et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: